Nextage Therapeutics (XTAE:NXTG) EBIT per Share : ₪-0.14 (TTM As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Nextage Therapeutics EBIT per Share?

Nextage Therapeutics's EBIT per Share for the six months ended in Dec. 2023 was ₪-0.06. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was ₪-0.14.

During the past 3 years, the average EBIT per Share Growth Rate was 37.50% per year. During the past 5 years, the average EBIT per Share Growth Rate was 41.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Nextage Therapeutics's EBIT per Share or its related term are showing as below:

XTAE:NXTG' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 37.5 Med: 45.4 Max: 57.3
Current: 37.5

During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Nextage Therapeutics was 57.30% per year. The lowest was 37.50% per year. And the median was 45.40% per year.

XTAE:NXTG's 3-Year EBIT Growth Rate is ranked better than
83.24% of 859 companies
in the Drug Manufacturers industry
Industry Median: 7.7 vs XTAE:NXTG: 37.50

Nextage Therapeutics's EBIT for the six months ended in Dec. 2023 was ₪-1.89 Mil.

Nextage Therapeutics EBIT per Share Historical Data

The historical data trend for Nextage Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nextage Therapeutics EBIT per Share Chart

Nextage Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-2.44

-1.40

-0.30

-0.21

-0.14

Nextage Therapeutics Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT per Share	Get a 7-Day Free Trial									-0.19	-0.11	-0.11	-0.08	-0.06

Nextage Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Nextage Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-4.153	/	29.181
=	-0.14

Nextage Therapeutics's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.89	/	29.438
=	-0.06

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₪-0.14

Nextage Therapeutics (XTAE:NXTG) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Nextage Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Nextage Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Nextage Therapeutics (XTAE:NXTG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nextage Therapeutics Ltd (XTAE:NXTG) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bio-Light, Kiryat Atidim 7, Entrance 1, 2rd Floor, Tel Aviv, ISR, 61581

Website

http://www.m-medic.com

Nextage Therapeutics Ltd is a holding company. The company, through its subsidiaries, is engaged in the development of biological marker, a molecule/gene, which when present in the body at abnormal levels indicates development of a disease. It is focused on the development and commercialization of cancer diagnostic products.

Nextage Therapeutics (XTAE:NXTG) Headlines

From GuruFocus

First Trust Global Portfolios Limited Announces Name Changes for Certain Sub-Funds of First Trust Global Funds plc

By Business Wire Business Wire • 01-29-2021